ROCKVILLE, Md., Sept. 13,
2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings,
Inc. (Nasdaq: SHPH), a discovery and development stage specialty
pharmaceutical company focused on improving the outcomes of cancer
patients treated with radiation therapy (RT), today announced its
commitment to improving outcomes for patients with prostate cancer
through its participation in the Hampton
University Proton Therapy Institute Prostate Cancer &
Men's Health Fair. The event, held on September 16, 2023 at Hampton University, is offering free early
detection exams for prostate cancer. Dr. Tyvin Rich, Shuttle Pharmaceutical's Chief
Medical Officer, will also be present to discuss the Company's
research on prostate cancer diagnostics and health disparities.
Prostate cancer is one of the most commonly diagnosed cancers in
men and is the second leading cause of cancer related deaths.
Prostate cancer health disparities studies have shown that
African-American men are at higher risk for developing prostate
cancer, as well as at higher risk of cancer specific death rates as
compared to Caucasian American men. According to the Hampton Roads
Prostate Health Forum (HRPHF), one in eight men will be diagnosed
with prostate cancer; and for Black men, the risk of dying from
low-grade prostate cancer is double that of any other race.
The causes of disparities have been attributed to socioeconomic
differences, environmental exposures and biological factors. Most
disparities studies have been population based, in part, due to the
lack of relevant in vitro and in vivo models to support biological
studies. Shuttle Pharma was awarded Phase I and II National
Institutes of Health (NIH) funded small business innovation
research program (SBIR) contracts entitled "Cell-based models for
prostate cancer health disparity research" to develop
African-American prostate cancer cell lines with donor matched
normal prostate epithelial cell lines from African American men.
Further, patients treated for prostate cancer may experience cancer
recurrence and treatment related late effects that adversely affect
quality of life and may prove life-threatening. Shuttle Pharma
recently completed Phase I and Phase II NIH funded SBIR contracts
entitled "Predictive biomarkers for prostate cancer patient
sensitivity for radiation late effects" to determine the technical
and commercial feasibility of a biomarker panel predictive of
radiation effects in patients treated for prostate cancer.
A manuscript titled "Novel paired normal prostate and prostate
cancer model cell systems derived from African American patients,"
was published by Shuttle Pharma's scientists describing the
prostate cancer cell lines derived from African American men for
precision medicine.
"Shuttle Pharmaceuticals is committed to the early detection of
prostate cancer and we are pleased to be a part of the Prostate
Cancer & Men's Health Fair hosted by the Hampton University Proton Therapy Institute,"
commented Anatoly Dritschilo, M.D.,
CEO of Shuttle Pharmaceuticals. "Our advancement of predictive
biomarker capabilities for prostate cancer patients and our
disparity research among African-American men are critical to the
general understanding of this deadly cancer."
To schedule your free PSA test and DRE exam, you can call
1-800-SENTARA or visit www.huptimenshealthfair.com.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (RT). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements." These statements include, but are not
limited to, statements concerning the development of our company.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the "Risk
Factors" section of Shuttle Pharma's Annual Report on Form 10-K for
the year ended December 31, 2022,
filed with the SEC on March 15, 2023,
its Quarterly Reports on Form 10-Q for the periods ended
March 31, 2023 and June 30, 2023, filed with the SEC on May 25, 2023 and August
14, 2023, respectively, as well other SEC filings. Any
forward-looking statements contained in this press release speak
only as of the date hereof and, except as required by federal
securities laws, Shuttle Pharmaceuticals specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D.,
CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharma-participates-in-hampton-university-proton-therapy-institute-prostate-cancer--mens-health-fair-301925696.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.